Ezose Sciences and Hirosaki University to Collaborate in Glycomics Research
News May 02, 2012
Ezose Sciences Inc. and Hirosaki University have announced that they have formed a collaboration in glycomics research to identify new biomarkers for use in predicting and monitoring the progression of prostate cancer and other urological cancers.
The research will examine serum and urine samples collected by Hirosaki clinical investigators from well-characterized patient and control populations in Japan.
Ezose will conduct the glycan analysis at its US laboratories using its proprietary GlycanMap® technology platform.
“This agreement marks another step that scientists at Ezose and in universities are taking together to improve our understanding of the role of glycans in health and disease,” said Hidehisa Asada, Ph.D., Vice President, Research & Development at Ezose.
Asada continued, “Given the already established clinical utility of glycan-based biomarkers in certain cancers, we believe that further studies in oncology hold promise for identifying other novel biomarkers that could help guide clinical practice.”
Chikara Ohyama, M.D., Ph.D., Professor and Chairman, Department of Urology at the Hirosaki University Graduate School of Medicine, said: “Glycomics is beginning to come into its own as a basic tool in biomedical research. We look forward to applying this new technology to unmet medical needs in managing urologic cancers through the complementary contributions of Ezose’s scientists and our own.”
Under terms of the agreement, Ezose is granted exclusive rights by Hirosaki University to develop and commercialize new biomarkers resulting from the collaboration.
Ingestible Drug-Delivery Materials May Improve Patient Treatment ComplianceNews
Hydrogel-based capsules could expand and reside in the GI tract for days, slowly releasing medication.READ MORE
Nanoparticle Delivery of Curcumin Induces Tumor Cell DeathNews
Attaching curcumin, a component of the common spice turmeric, to nanoparticles can be used to target and destroy treatment-resistant neuroblastoma tumor cellsREAD MORE
Acquisition Sees Agilent Gain Powerful NGS IP PortfolioNews
Agilent Technologies announces its acquisition of the molecular and sample barcoding portfolios of Population Genetics Technologies.READ MORE
Comments | 0 ADD COMMENT
International Conference and Exhibition on Nanomedicine and Nanotechnology
Nov 23 - Nov 24, 2017
11th Edition of International Conference on Proteomics 2018
Mar 22 - Mar 23, 2018